Drug Profile
Research programme: ultra-long acting therapeutics - AbbVie/Lyndra
Latest Information Update: 28 Feb 2023
Price :
$50
*
At a glance
- Originator Allergan; Lyndra
- Developer AbbVie; Lyndra
- Class Antidementias; Antipsychotics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease; Schizophrenia
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for preclinical development in Schizophrenia in USA (PO, Controlled release)
- 28 Oct 2021 No recent reports of development identified for research development in Alzheimer's-disease in USA (PO, Controlled release)
- 08 May 2020 Allergan has been acquired and merged into AbbVie